R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation
Authors:
Open Access
- 15 September 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (9) , e3003996
Abstract
R1-32-like public antibodies, characterized by shared IGHV1-69/IGLV1-40 usage, are elicited in more than 50% of individuals with COVID-19 and have been implicated in driving recurrent mutations at L452 SARS2 and F490 SARS2 within their convergent epitope in the SARS-CoV-2 spike receptor-binding domain. These mutations effectively mediate escape from non-affinity-matured R1-32-like antibodies with germline-like sequences. Here, we characterize four affinity-matured human R1-32-like antibodies, C092, C807, BD56-104, and BD56-597, that tolerate L452 SARS2 and F490 SARS2 mutations. We show that this tolerance arises from residues introduced by somatic hypermutation at convergent positions across multiple CDR loops and surrounding regions, thereby creating additional contacts that reinforce epitope binding. An unusual N354 SARS2 glycosylation site, which emerged in BA.2.86 and became fixed in its descendants, is linked to escape from affinity-matured R1-32-like antibodies, implying ongoing selection by this public antibody class. Using an AI model trained on extensive neutralization data, we further identified ZL525, an ultrapotent human R1-32-like antibody with pan-SARS-CoV-2 variant activity, including against the highly evasive KP.3 variant carrying the N354 SARS2 glycosylation, and broad sarbecovirus cross-reactivity extending to SARS-CoV-1. Together, these findings show how affinity maturation enables public antibodies to adapt to viral antigenic drift, reveal how public antibody responses contribute to shaping SARS-CoV-2 antigenic evolution, and demonstrate the potential of AI-empowered strategies for discovering broadly neutralizing antibodies.Keywords
Funding Information
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project (2026ZD01999601)
- the Major Project of Guangzhou National Laboratory (SRPG22-002)
- the Major Project of Guangzhou National Laboratory (GZNL2026C01003)
- the Major Project of Guangzhou National Laboratory (EKPG21-30-2)
- the Major Project of Guangzhou National Laboratory (GZNL2025A0009)
- National Key Research and Development Program of China (2021YFA1300903)
- National Natural Science Foundation of China (82341085)
- National Natural Science Foundation of China (32570199)
- National Natural Science Foundation of China (82495200)
- National Natural Science Foundation of China (82495203)
- National Natural Science Foundation of China (32361163669)
- National Natural Science Foundation of China (32170189)
- National Natural Science Foundation of China (32241021)
- National Natural Science Foundation of China (92469301)
- National Natural Science Foundation of China (82201932)
- Science and Technology Planning Project of Guangdong Province (2023B1212060050)
- Science and Technology Planning Project of Guangdong Province (2023B1212120009)
- Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBHBRP24-02)
- the 111 Project (D18010)
- Natural Science Foundation of Guangdong Province (2025A1515011245)
This publication has 63 references indexed in Scilit:
- An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spikeCell Reports, 2024
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2Cell Reports, 2022
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsCell Reports, 2022
- Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody bindingCell Reports, 2021
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individualsCell Reports, 2021
- Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional speciesImmunity, 2021
- Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody classCell Reports, 2021
- Maturation and persistence of the anti-SARS-CoV-2 memory B cell responseCell, 2021
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004